Abbott Laboratories (NYSE:ABT) operates in the healthcare sector, where results can shift with product-cycle timing, ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Lab personnel say worries are mounting over the safety of a rapid coronavirus test by Abbott Laboratories that President Donald Trump has repeatedly lauded ― particularly, the risk of infection to ...

Abbott Laboratories, Inc. ABT recently announced the receipt of the FDA approval for the Alinity i laboratory traumatic brain injury (TBI) blood test. This will be the first commercially available TBI ...

In recent weeks, Abbott Laboratories raised its quarterly dividend for the 52nd consecutive year and secured CE Mark approval ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The North Chicago company said ...

The consensus rating for Abbott Laboratories is Outperform, based on 3 analyst ratings. With an average one-year price target ...

Abbott Laboratories (NYSE:ABT) Q4 2025 Earnings Call Transcript January 22, 2026 Abbott Laboratories reports earnings inline with expectations. Reported EPS is $1.5 EPS, expectations were $1.5.

Abbott Laboratories fell on its latest earnings report, but I view this as a buying opportunity. Read the latest analysis on ...

The medical-products maker’s shares tumbled after its quarterly profit and sales underwhelmed investors.